Clinical studies

Since 2001, the Hexacath clinical programme has enrolled thousands of patients internationally and has established the proven efficacy and safety of the Titanium Nitride Oxide coated stents in various population subsets such as Acute Coronary Syndrome patients, small vessels or diabetics. Randomized studies have demonstrated the superiority of this technology versus the first generation DES and its non inferiority versus the most recent DES generations with a trend towards higher safety as soon as 18 months after implantation. At last, Titanium Nitride Oxide Bio Active Stents require only a short term dual anti platelet treatment post stenting.


August 2016

International Journal of Cardiology

Long-term clinical outcome of titanium-nitride-oxide-coated stents ver...

July 2016


Novel monorail infusion catheter for volumetric coronary blood flow me...

August 2013

Annals of Medicine

Stent-oriented versus patient-oriented outcome in patients undergoing ...

August 2013

Cardiovascular Imaging

Neointimal coverage and vasodilator response to titanium-nitride-oxide...

April 2013

Minerva Cardiologica

Outcome of ST-elevation myocardial infarction versus non-ST-elevation ...

November 2012

International Journal of Cardiology

Five-year clinical outcome of titanium-nitride-oxide-coated bioactive ...